Sumatriptan
(Redirected from Imigran)
Sumatriptan, a member of the triptan class of medications, is a widely used treatment for migraine and cluster headaches. Recognized for its vasoconstrictive properties, Sumatriptan functions by selectively binding to and activating serotonin 5-HT1D receptors located in the central nervous system (CNS). This action leads to the constriction of cerebral blood vessels, often resulting in headache relief.
Mechanism of Action[edit | edit source]
The primary mechanism of Sumatriptan's efficacy lies in its interaction with the 5-HT1D receptors in the CNS, which results in cerebral vasoconstriction. As the dilation of blood vessels is believed to be related to migraine and cluster headaches, Sumatriptan's ability to induce vasoconstriction may lead to relief from these conditions.
Additionally, Sumatriptan may influence the pathophysiology of migraines by decreasing the release of vasoactive neuropeptides from the trigeminal nerve's perivascular axons within the dura mater. It also potentially reduces the extravasation of plasma proteins, thereby reducing inflammation. Furthermore, it may suppress the release of other inflammation mediators from the trigeminal nerve.
Clinical Use[edit | edit source]
Sumatriptan is indicated for acute treatment of migraine attacks with or without aura, as well as the treatment of cluster headaches. It is not designed for prophylactic therapy to prevent future attacks or to reduce the frequency of attacks. It should only be used where a clear diagnosis of migraine or cluster headache has been established.
Adverse Effects[edit | edit source]
The most commonly reported side effects of Sumatriptan are tingling, warmth, flushing, and feelings of discomfort or pressure, which are generally transient. More serious side effects such as chest pain and tightness may occur and require medical attention. Sumatriptan should be used with caution in individuals with underlying heart conditions due to its vasoconstrictive action.
Pharmacokinetics[edit | edit source]
Orally administered Sumatriptan is well absorbed in the digestive tract but has low bioavailability due to first-pass metabolism in the liver. It is primarily excreted in urine, with a minor amount excreted in feces. The half-life of Sumatriptan is approximately 2.5 hours.
| Sumatriptan Resources | |
|---|---|
|
 |
See Also[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
